The Capital Allocation & Investments team is a new function within Agilent that will play a critical role in shaping capital deployment strategy, driving financial analysis, and decision-making across M&A, organic growth (e.g. new product launches), and portfolio optimization initiatives. The team partners closely with Corporate Development and serves as a key advisor to senior leadership across business groups, finance, and other functional stakeholders.
Reporting to the Director, Capital Allocation & Investments, the Manager is responsible for leading financial analyses in support of high complexity projects, with a primary focus on M&A. Over time, this role will also play a key role in developing core frameworks and infrastructure to enhance capital allocation discipline.
Occasional
Day
No End Date
Finance
Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product solutions and services portfolio. Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Our teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories. Additionally, the unique expertise of Agilent’s CrossLab and technical teams provides valuable insight and support to our customers, helping them fully optimize their laboratories and resources to better focus on what's important: bringing great science to life. In fiscal 2022, Agilent Technologies generated revenue of (US) $6.85 billion.